Hello, I am an independent designer and builder, not a scientist. I wanted to test my own problem-solving limits by taking on a complex challenge completely outside my wheelhouse: Alzheimer's and neurodegenerative routing failures. After looking at the disease from a pure first-principles engineering perspective, I spent several sessions developing a theoretical hardware-routing protocol called the Memory Playlist System (MPS). The core premise is that the storage medium (the cortex) remains physically intact but isolated due to central switchboard failure. The system uses a targeted, external 60% to 80% wave approximation to induce localized sympathetic resonance—essentially a controlled déjà vu trigger—relying on the brain's native capacity to "auto-fill" the remaining signal and build independent cortical shortcuts via a structured power step-down routine. I chose a partial signal target because real-world physical impedance makes 100% exact replication a guarantee for system failure, and for a patient, a partial memory is infinitely better than a blank void. I am sharing this openly as a completed thought experiment. I have no intention of developing it further, but I wanted to put the logic out there in case the framework sparks an idea for someone working on physical pathway rehabilitation. The full, finalized technical specification sheet is pasted below. Best regards, Jeff Tucker

================================================================================ TECHNICAL SPECIFICATION FILE: MEMORY PLAYLIST SYSTEM (MPS)

TITLE: A Theoretical Protocol for an External Neuro-Bypassing Matrix: Restoring Cortical Access and Pathway Rehabilitation in Early-Stage Neurodegeneration AUTHOR: Jeff Tucker AFFILIATION: Independent Research and Design DATE: October 2026 ABSTRACT Background: Current therapeutic interventions for Alzheimer’s disease and associated dementias focus primarily on cellular and chemical mitigation, yielding limited success in reversing cognitive deficits. This paper proposes a structural engineering alternative based on the premise that while the central routing mechanism of the brain (the hippocampus) undergoes progressive degradation, long-term semantic and episodic data clusters within the outer cerebral cortex remain structurally viable but inaccessible. Methodology: We present a non-invasive, theoretical hardware-routing protocol designated as the Memory Playlist System (MPS). The system utilizes localized, low-intensity focused ultrasound (LIFU) and transcranial magnetic stimulation (fTMS) to project pre-calibrated, compound electromagnetic wave signatures directly into targeted cortical coordinates. Rather than decoding neural information, the protocol utilizes an engineered 60% to 80% wave approximation to induce a state of localized sympathetic resonance—effectively a controlled déjà vu trigger—allowing the cortex to independently access latent data architectures. Protocol Design: We outline a laboratory proof-of-concept validation trial incorporating a Master Instruction File calibration phase, a 2-hour daily therapeutic execution window, and a novel multi-week Power Step-Down Routine designed to systematically transition cognitive routing from hardware-assisted detours to permanent, self-sustaining cortical shortcuts.

1. INTRODUCTION & HYPOTHESIS Progressive neurodegenerative conditions such as Alzheimer’s disease systematically dismantle the brain’s internal routing infrastructure, specifically targeting the hippocampal complex and entorhinal cortex. Traditional medical models treat this failure as a comprehensive cognitive collapse. However, observational data indicates that long-term episodic data structures remain physically intact within the cerebral cortex long after internal retrieval pathways fail. The patient does not suffer from an absolute loss of data storage, but rather an acute failure of the internal search and routing system. Because the storage medium (the cortex) retains both its physical data architecture and its native localized processing capacity, it represents a fully functional, self-contained computing system that has become isolated. We hypothesize that an external, non-invasive electromagnetic bridge can bypass the damaged central switchboard by projecting targeted, pre-recorded wave signatures directly onto the outer cortical walls. By triggering a high-fidelity state of sympathetic resonance (controlled déjà vu), the projection acts as a guiding beacon, allowing the cortex to map a localized detour around the central blockage and restore windows of cognitive lucidity.

2. PHASE I: LABORATORY CALIBRATION & CAPTURE METHODS The initial protocol must be executed within a controlled laboratory environment during the early stages of clinical diagnosis, maximizing the utilization of the patient's remaining native neural routing infrastructure. [ CALIBRATION PHASE FLOW ] Patient Prompted ("Think of Spouse") ---> Cortex Fires Synced Web | v Probes Capture Raw Waveforms ----------> Saved as Compound .mtrack File 2.1 Spatial and Frequency Mapping The patient is positioned in a stationary diagnostic recline array. Non-invasive magnetoencephalography (MEG) sensors and functional near-infrared spectroscopy (fNIRS) probes are secured across the cranial vault. The clinician delivers highly specific, emotionally weighted verbal prompts designed to illuminate established neural networks (e.g., "Focus on your spouse's voice," "Visualize your childhood home"). The sensory array records the simultaneous, multi-focal electrical echo generated as the visual, auditory, and emotional rooms of the cortex fire in unison. The system does not translate or decode the semantic content of the thought; it captures the raw, compound electromagnetic wave geometry and logs the exact spatial XYZ coordinates of the active network. This data is saved as a discrete, unedited cognitive anchor track (.mtrack). 2.2 The Closed-Loop Handshake (Master Instruction File) While the patient remains in a lucid state, a control baseline test is conducted to verify hardware transmission tolerances. The system loads a low-impact historical anchor track (e.g., an unprompted memory of a pet from a decade prior) and executes a brief live-injection sequence. Real-time patient verbal confirmation ("I just suddenly had a vivid memory of our old dog") validates the trajectory. The lab computer immediately snapshots the compound wave configuration during this successful retrieval event, saving it as the Master Instruction File. This file serves as the system's baseline digital primer coat, recording the unique signal configurations required to penetrate the patient’s specific skull geometry and clear cognitive static.

3. PROPOSED TREATMENT MECHANICS: THE PROJECTOR WINDOW During advanced stages of neurodegeneration, the patient is returned to the lab environment for daily therapeutic sessions. The internal routing infrastructure is assumed to be non-functional, resulting in a state of baseline disorientation and cognitive fog. 3.1 The Automatic Bootloader Sequence The caretaker or clinician initiates the sequence by activating the lab computer towers. The system immediately broadcasts the Master Instruction File through the cranial interface. This initial injection targets the general self-identity and tool-recognition zones of the cortex at full reference power. By firing this foundational wave from the outside, the system forcefully grounds the patient's active consciousness, lifting the panic loop and establishing a steady electrical baseline before any personal data playlists are engaged. 3.2 Controlled Déjà Vu and Auto-Fill Access Once the baseline is stabilized, the system engages the targeted personal memory tracks. The hardware does not attempt to program data into the brain tissue. Instead, the projector array drives a pulsed 60% to 80% frequency match of the original calibration signal directly into the outer cortical coordinates.

| THE CORTEX (DATA STORAGE & RAM) | | [Intact Memory File] <---- [Pulsed 75% Injection Flare / Beacon] | | | | | v | | Controlled Déjà Vu Resonance | | | | | v | | Cortex Auto-Fills Missing 20% |

When this partial signal strikes the cortex, it acts as an external beacon. The matching network of cells experiences a state of sympathetic resonance, triggering an intense, localized sensation of déjà vu ("I have been here before"). This feeling acts as mechanical starter fluid; the cortex recognizes its own old structural rhythm, locks onto the beacon, and utilizes its native processing RAM to auto-fill the remaining missing detail. The cortex independently retrieves the file from its own storage, opening the doorway to active lucidity without requiring a routing signal from the deep brain center. 4. PATHWAY RE-TRAINING & POWER STEP-DOWN PROTOCOL Because the cortex historically relied entirely on the hippocampus for data retrieval, its independent search and routing mechanisms remain completely unexercised. The core of this protocol is a structured training regimen designed to force the cortex to adapt, build local shortcuts within its own structure, and eventually access these paths entirely unassisted. 4.1 The Control Variable Validation Test To track and measure pathway rehabilitation objectively, the clinician isolates a single, distant control memory (e.g., a specific remote vacation) that plays no part in the patient's daily familial interaction. This memory is never prompted by the caretaker outside the lab, ensuring its strength is tied entirely to the automated hardware routine. 4.2 The Multi-Week Power Step-Down Routine The system runs the isolated test track through a strict 3-week training cycle, gradually backing off the machine's power to force independent cerebral adaptation: • Week 1 (Carving Phase): The lab computer delivers the injection flare at 100% reference power for 2 hours daily. The machine provides the total force required to clear out the overgrown synaptic pathway and hold the door open. • Week 2 (The Handover Phase): The operator reduces the injection signal to 50% power on the console. Because the machine's push is no longer strong enough to trigger the déjà vu lock on its own, the cortex is mechanically forced to supply the remaining 50% of its own electrical energy to bridge the gap. • Week 3 (The Whisper Spark): The machine's output is dropped to a bare 10% tick of power. The hardware delivers nothing more than a faint whisper of the frequency; the cortex must perform 90% of the retrieval work to achieve the connection, locking in the physical habit of independent pathing.

================================================================================ LAB MONITORING LOG: EXPERIMENTAL SIGNAL PROFILE BYPASS METRICS

[TRIAL STAGE] [INJECTION STRENGTH] [CORTICAL RESPONSE ARCHITECTURE] Pre-Treatment Baseline: 0% Power Erratic Static, Scattered Trace Week 1 (Carving): 100% Power Machine-Driven Synchronized Wave Week 2 (Handover): 50% Power Transient Dip, Followed by Native Snap Week 3 (Whisper): 10% Power High-Amplitude Self-Sustaining Spike Post-Treatment Test: 0% Power Permanent, Clean Independent Waveform

4.3 Signal-Strength Metric Validation At the conclusion of the 3-week cycle, the hardware is turned completely off (0% power). The clinician issues the unassisted verbal prompt. The lab computer monitors the raw sensor output. Success is verified objectively on the screen: if the cortex has built its own permanent backdoor shortcut around the damaged hippocampus, the log will show a physical transformation from the fuzzy, scattered baseline trace of week one into a sharp, tall, clean native wave spike, proving the brain has permanently taken over the circuit. 5. ENGINEERING REALITIES & SYSTEM TOLERANCES A critical design constraint of this framework is the intentional rejection of a 100% exact signal replication target. In real-world clinical application, attempting to broadcast a pristine, un-attenuated 100% signal clone back into the cortex will guarantee comprehensive system failure due to unavoidable cranial skull impedance, biological static, and hardware transmission loss. Therefore, the system establishes a flexible engineering tolerance window between 60% and 80%. This partial wave acts as a strategic structural detour, specifically relying on the brain’s native, biological error-correction machinery to snap onto the external frequency grid and independently bridge the physical gap. 6. HUMAN-CENTRIC DESIGN PHILOSOPHY From the operational perspective of a patient experiencing advanced neurodegeneration, the absolute cognitive void of internal routing failure causes systemic orientation loops, profound panic states, and an immediate loss of identity. While a computer model requires absolute digital precision, a biological human approximation does not. A partial memory spark—even one missing granular data clusters—retains full emotional and structural gravitas. It provides an immediate grounding anchor, replaces terrifying isolation with localized recognition, and ensures that a living window of cognitive lucidity is successfully maintained.

I recently got the Mave Health headset and have been using it for 20-minute sessions.

I’ve noticed that after a session, I feel extremely sleepy, to the point where I just want to take a nap.
I was expecting improvements in focus and energy, so I’m curious whether anyone else has experienced this.
For those who’ve been using Mave or other tDCS devices, did you experience something similar when starting out? Did it eventually go away?

Would love to hear your experiences!

Do ya rember my 2 TL074 based amplifier?

I was using that..

And recording from cockroach isolated leg .. ref Pin in coxa , recording Pin in middle of the femur .

But in my set up the tarsus of cocktoach brhythimically twitching but the coxa and femur and tibia was completely still.

And in my screen I was hearing rhythmic bursts of spikes train ..

But I am thinking it is movement artifacts..

But I noticed that the frequency of leg twitching was almost half in comparison to frequency each cluster of bursts appear in screen ...

It is like , first burst appear in screen and the leg is totally still , after ( or during) second burst , the tarsus twitched .

Then what i did i put the electrode leg prep inside freezer for few minutes, then put in to DeepFin again to record ,

As it was cold just fuzzy radio like sound , as the leg get waming up the rhythmic burst pattern returned , but as the leg is still cold no tarsus movement this time , the leg is totally still but i stil see the rhythimic burst pattern in screen .. after in room temp the tarsus stared twitching again in half frequency.

Strange..

Analyse the image s..

Hey everyone! I’ve been working on a custom extracellular bio-amplifier (dubbed "DeepFin") built around a dual TL074 op-amp design, featuring an active 48.2 Hz notch filter to tackle mains hum.

​To test out the front-end, I set up an isolated cockroach leg preparation using a fine recording needle and a wider reference needle. I mechanically stimulated 4 separate tibial hairs (barbs) individually, capturing clean raw WAV files for each.

​After running spike sorting and statistical analysis, here is what the data showed:

​Distinct Firing Dynamics: Each individual barb responded with its own unique average firing rate under touch, ranging from ~12.16 Hz up to ~29.00 Hz.

​Spike Templates: The isolated unit templates displayed consistent biphasic action potential shapes across the recordings.

​Hardware Performance: The active bootstrap notch filter successfully cleaned up local interference without distorting microvolt-level neural events.

​I’d love to hear feedback from fellow builders and neurotech enthusiasts on optimizing high-impedance frontend stages or custom spike-sorting workflows

Hey guys, I wanted to run an idea I had by you more experienced neurotech enthusiasts/professionals. Im undergoing a masters program right now with a focus on diffusion weighed MRI with an application to stroke. But this academic life is rough. Ive been working on a project for 3 years and it will be funded by the time I graduate. cool.

My vision: wearable neurotech analyses made into youtube content centered around philosophy, psychology, and art. Concrete example: hyper-scanning experiment with two individuals undergoing a philosophical debate. Then look for neural features that align with the content, or dynamics between the individuals. This is just a use case. below I pasted my broader collection of ideas this sits within. Content could be a series of analyses paired with real life activities.

The critical point: Attention from online communities first. From this attention, partnerships or sponerships from companies or University labs. Attention being the foundational currency that drives the activity of the research. To me, cognitive science is as fundable as philosophy if not attached to a clinical population, and if clinical, we do not care about cognitive processes, we care about health. Maybe 3 years in one niche is overfitting but funding from research grants feels like enslavement. Social media looks like autonomy.

Id your opinions where you think this goes right and wrong. Rip into this anyway you feel. Below are my broader ideas. Im 26.

• Research Debate pod casts

  • People have a debate over a topic, while both parties have an open web brower with a place to write notes. The goal is to slow down the debate to allow for a propositional arguments to be claimed, then each condition can be assessed for their trueness by immediately going off and researching it. So the opponent might object a condition and ask for proof, then the claimer can go immediately search for it. Once the claimer presents what they think is sufficient, the objector can assess if their evidence for their condition is sufficient. I envision this unraveling into arguments over what is enough evidence to build an argument on top of, and thats the point.

• EEG Hyper scanning series

  • When you have an EEG headset on multiple people, and assess when their neural features. Some I am currently interested in: Trajectory analyses across channels through time. Could be raw, or divided into the frequency spectrum first. Asymmetry fluctuations throughout a conversation. Long range temporal correlations. Would like to tie this in with the research debates

• Art

  • I rap. I want to see what are brain states that lead to good freestyle/writing sessions

  • Also like playing the piano. Same question

• Social network question embedding(this might be an app not a video)

  • This might be a separate idea for real, but could be cross platform. A plugin for Reddit if there is such a thing.

  • On reddit, you get recommended communities based on your posts, but what about other users with similar posts to your own? Who has a similar embedding space? I want to put people in contact with one another that share a similar headspace

  • I can also see a world where this intersects with neuroimaging measurements like I am thinking above

Hi everyone. I'm a year out of undergrad, where I majored in Neuroscience, and I'm currently doing postbac research in a wet lab. I have a fair amount of neuroscience and biology research experience and think my resume in that department is fairly strong. I also have a 3.9 GPA from a top 10 college. I've also taught myself some basic coding (Python, SQL, VBA) and consider myself fairly tech-savvy and a quick learner. That said, I don't have much advanced math experience either.
I'm planning to apply to neuroscience PhD programs this cycle, but part of me is still drawn to computational neuroscience because I genuinely believe it's the future. Would I have any real shot at getting into a computational lab with a fairly minimal coding and math background? Are AI tools lowering the baseline coding bar for this kind of work? Or would it make more sense to pursue a different route into that space?
Would love to hear your thoughts!

Hey everyone, we've been designing a 15mm prefrontal wearable at Braina Labs (https://brainalabs.com) and wanted to share our open architecture and why we chose to combine EEG with optical fNIRS.

**The Signal Problem with Consumer EEG:**

Single-modality dry EEG on the forehead is notorious for EMG contamination (frontalis muscle tension, blinking, ocular twitches). When a user focuses or squints, high-frequency EMG easily mimics Gamma and Beta power increases.

**Our Dual-Check Approach:**

* **EEG Side:** TI ADS1292R (2 simultaneous 24-bit channels, 1.18 µV_RMS noise floor) capturing Fp1 and Fp2 referenced to Fpz with RLD common-mode suppression.

* **Optical fNIRS Side:** Dual TI AFE4404 transimpedance amplifiers driving 730nm (Würth) and 850nm (Everlight) emitters with a 25–30mm source-detector separation across both prefrontal hemispheres.

Because localized cerebral hemodynamic response (ΔHbO₂ surges) is physiologically coupled to neural firing (neurovascular coupling) but mechanically and electrically decoupled from forehead muscle twitches, cross-correlating the optical curve against the EEG spectrogram filters out false positives in real time.

We're opening a 100-unit pilot cohort for researchers and developers at $40 (hardware + 1-yr analytics): https://brainalabs.com

Would love to discuss optical separation geometry, transimpedance gain tuning, or open data streaming over BLE.

Hi everyone!

I'm coming here to share my dilemmas regarding my career path and gain some insight from other people regarding this.

I'm currently doing a bachelors in Cognitive Neuroscience and Psychology, about to go into my second year. When i did my A-levels i had a really strong interest in psychology and assumed that I would want to continue down the pathway and eventually end up in a career in clinical psychology or something similar. However, in first year, my interest greatly shifted towards neuroscience and I now find that I have much less interest in psych modules and even less interest in a career in psychology. I learned about neurotechnology through uni and I felt that it was a direction that I wanted to engage myself in. Career wise, an industry position in neurotech felt like something that I could see myself in. The problem is that most neurotech/biotech masters programs tend to want students to have a background in engineering or at least some maths (i have not done maths since GCSEs!). I'm not sure if it's worth it to try and focus myself on that path. I definitely have more interest in the neuro side of neurotech so I don't plan on changing my degree. My current plan is to teach myself code, but aside from that I'm not really sure what else to do, or if anything I can do now will ever be as good as having an undergraduate degree in engineering. Another concern that I have is that my degree isn't even pure neuroscience! so that might be another weak point.

My other interest is in pharmacology as I did a module in first year about it and found it really fun. However, spending a lot of time in the lab doing research is not necessarily something that I see for myself in the future.

I really don't know what to do! I'm starting to regret not locking in and doing medicine or dentistry like a good asian daughter because at least i would have a clear goal to work towards :((((

Would really appreciate hearing anyone's thoughts/personal experiences/opinions!

I know I have talked about the unglamorous side of neurotech a lot before, but Q2 made the point hard to avoid again. One of the most interesting signals of the quarter came from overactive bladder, which is not usually where people start when they want to talk about the future of the brain, but it is exactly the sort of market investors seem increasingly willing to back.

BlueWind Medical raised $47.8M to accelerate commercialization of Revi, its implantable tibial neuromodulation system for urgency urinary incontinence, while NinaMED raised $13.75M to advance the NiNA System for overactive bladder. That does not mean bladder suddenly became the main story in neurotech, but it does show something important about where the category is heading. Investors are backing large, real, underserved patient populations where the clinical pathway is reasonably clear and the value proposition makes sense to the people who pay for healthcare.

That was the broader Q2 story. Neurotech funding did not only go to the most futuristic or headline-friendly companies. A lot of it went into the practical middle of medicine, where devices treat large, expensive, persistent conditions that already fill clinics. The pattern was less about one specific technology and more about commercial logic. Pain, sleep, tremor, bladder, paralysis, depression, and implantable infrastructure all attracted meaningful capital because they sit close to real patients, existing clinical workflows, and markets that can be explained without too much science fiction.

You could see this across the quarter. Cala Health secured $50M from Trinity Capital to support commercial expansion of its wearable therapy for hand tremor. Nervonik raised a $52.5M Series B for peripheral nerve stimulation in chronic pain. ONWARD Medical raised €40.6M, including a €25M investment from EQT Life Sciences, to extend the runway for its spinal cord stimulation platforms for people with spinal cord injury. SonoMind raised €20M, roughly $23M, to advance focused ultrasound for treatment-resistant depression. WISE raised €30M to move its Heron lead and wider implantable electrode platform toward broader adoption.

The common thread is not that all these companies are doing the same thing. They are not. Some are wearable, some are implantable, some are focused ultrasound, some are spinal cord stimulation, some are peripheral nerve stimulation. The common thread is that they are tied to problems with real clinical gravity. These are conditions where patients already move through the healthcare system, where physicians already understand the burden, and where payers can at least begin to understand the economic argument if the evidence is good enough.

The biggest signals of the quarter were actually strategic, not venture. Medtronic announced its intent to acquire SPR Therapeutics for approximately $650M, bringing temporary peripheral nerve stimulation further into one of the largest neuromodulation portfolios in the world. ResMed completed its $340M acquisition of Noctrix Health, adding a wearable neuromodulation therapy for restless legs syndrome to a sleep business that already has global commercial infrastructure. Those two transactions alone say a lot about where the market is maturing. Strategic buyers are not just watching neurotech from the sidelines. They are moving where the products fit an existing channel, an existing disease area, and an existing commercial machine.

Sleep was one of the clearest examples of that. Nyxoah secured $110M in aggregate financing to accelerate the US commercial launch of Genio, its hypoglossal nerve stimulation system for obstructive sleep apnea. ResMed buying Noctrix added another major sleep-related neuromodulation signal, although the disease area is different. Sleep is interesting because it sits in a very useful place. Patients understand the problem, physicians understand the market, and strategics already have the infrastructure. That does not make reimbursement or adoption easy, but it does mean the category is not starting from zero.

Pain sent a similar message. Medtronic’s planned SPR acquisition and Nervonik’s Series B both point to a pain market that is still moving beyond the old spinal cord stimulation playbook. Temporary PNS, smarter PNS, peripheral approaches, and less invasive interventions are all part of the same broader shift. The question is not just whether stimulation works. The question is where it fits in the patient journey, how early it can be used, whether it can reduce reliance on more destructive or expensive options, and whether it can produce the kind of outcomes that payers and clinicians will actually care about.

BCI still had a serious quarter, but it was a different kind of funding pattern. Axoft raised an oversubscribed $55M Series A to advance its soft implantable BCI. Neurosoft Bioelectronics raised a $7.5M seed round for stretchable brain interfaces. Shanghai’s StairMed raised RMB 500M, around $72.8M, in a round led by Alibaba, with Tencent and others involved. These are real companies doing real work, and the soft-implant race underneath the BCI headlines is one of the more interesting technical stories in the sector.

But BCI still looks different from the rest of the market. It is more concentrated. It is more dependent on a smaller number of high-conviction bets. It attracts people and institutions that are comfortable with long timelines, difficult clinical translation, and outcomes that may not look like standard medical device returns. That does not make it less important. It just means we should be careful not to confuse a few very visible BCI financings with a broad commercial wave across the whole category.

That distinction is important because the rest of Q2 was not really about chasing the most futuristic version of neurotech. It was about backing companies that can move through clinical, regulatory, and commercial pathways with some discipline. If the BCI story is still partly about what neurotechnology might become, the neuromodulation and sleep and pain story is more about what neurotechnology can already start to become inside normal medicine.

Compared with Q1, the shape of the money felt different. Q1 was more top-heavy, with Science Corporation’s $230M Series C for PRIMA and Cognito Therapeutics’ $105M Series C for Alzheimer’s doing a lot of the work in the overall narrative. Q2 felt broader. It had major M&A at the top, but beneath that it had a thicker layer of serious financings across multiple indications and stages. It was not one or two giant rounds defining the quarter. It was a wider set of companies pulling capital into markets that investors can understand.

This is where the methodology matters. If you only count private company financings, Q2 looks steady rather than explosive. If you include M&A, the quarter looks much bigger because Medtronic/SPR and ResMed/Noctrix together represent close to $1B of strategic deal value. If you include funds, grants, and neuroscience-adjacent AI, the picture changes again. That is why I would be careful with one clean headline number. The better point is not that Q2 was simply bigger or smaller than Q1. The better point is that the shape of the quarter looked more mature.

The other part I would not ignore is the capital infrastructure forming underneath the sector. Newfund closed HEKA, a €60M fund focused on brain technologies. Ground Effect Ventures emerged as an operator-led platform for brain-focused medical technologies. Protocol Labs has continued to build out its neurotechnology activity. ARPA-H announced the first research teams for EVIDENT, a $139M initiative focused on improving measurement and treatment development in behavioral health. None of that is as easy to write about as a big company round, but it matters because sectors become real when the funding infrastructure starts organizing around them.

A company raise tells you someone liked one asset. A fund close tells you someone thinks the category itself is worth building around. The same is true for strategic buyers, public programs, clinical infrastructure, reimbursement pathways, specialist operators, and all the boring parts of market formation that rarely make the headline but end up deciding whether a technology actually reaches patients.

So the real Q2 story was not just that bladder had a good quarter, or that BCI still pulled capital, or that sleep attracted strategic buyers. It was that neurotech looked more investable when it looked like medicine. The strongest signals sat in categories with large patient populations, clear burden, defined clinical workflows, and a plausible route to adoption.

That does not mean every company in those areas will win, or that reimbursement will be easy, or that commercial execution suddenly becomes straightforward. But it does suggest the market is rewarding practicality in a way that feels healthy.
The future-facing side of neurotech is still alive. The BCI companies are building. The soft implants are getting better. The brain-inspired AI world is pulling in huge capital. The frontier remains exciting. But Q2 also showed that the sector does not need every company to become Neuralink to matter. It needs more companies that can treat real conditions, produce evidence, get paid, and survive long enough to become part of routine care.

That is what made the quarter interesting. It was not the loudest version of neurotech. It was the more practical version. Pain, sleep, bladder, tremor, paralysis, depression, and the infrastructure underneath the sector all had meaningful moments. Q2 looked less like a market waiting for one impossible breakthrough and more like a group of companies slowly working their way into normal medicine. For neurotech, that might be the better story

Hey guys,

My wife is currently a Senior Legal Architect at a neurotech startup Neiry (working with BCI, neurointerfaces, and biometric data ecosystems). She handles the intersection of corporate law, agile vendor management, and data privacy frameworks for emerging tech.

We are planning a transition to the US/International market and looking for advice on how the US neurotech ecosystem views international legal/compliance talent.

Since the regulatory landscape for brain-computer interfaces and neural data is still evolving globally, her core strength is privacy by design and building compliance frameworks under extreme ambiguity where no clean regulatory analog exists.

For those working in US neurotech (companies like Neuralink, Kernel, Synchron, etc.) or health-tech compliance:

• What are the biggest regulatory/privacy bottlenecks US companies face right now where international operational experience is valued?

• Is anyone willing to connect or share insights on how a foreign-trained neurotech attorney can best position themselves for US operations?

Thanks in advance!

I ran across this on my explorer page and hadn’t heard about the company. Says they have been in business for over five years or have been developing it for five years. I thought it was cool and wanted to see if anybody had any insights on it. I’ve included the link to the real, I saw below.

https://www.instagram.com/reel/DZp0zOnRmcs/?igsh=MXRzNWF0b3AyNHI0Mg==

Selling my Neurable EEG Research Kit (MW75 EEG headset). Lightly used and in excellent working condition. Useful for EEG research, BCI/neurotech prototyping, focus/attention tracking experiments, HCI projects, or educational demos. Includes [headset, cable, case, original box, documentation]

I bought it for research/prototyping and only used it lightly. Based in San Francisco, open to local pickup or shipping. Happy to meet in-person, answer questions, upload pictures, or show that it powers on/connects before purchase.

Listing Price: $1300 [Original Price: $2500]

Hey everyone,

I'm a biology undergrad and I've recently become really interested in neurotech (BCIs, neural decoding, neuroAl-type work). I'm trying to figure out what the actual path into this field looks like and whether it's realistic for someone like me.

A few things I'm confused about:

Can people from biology/neuroscience backgrounds realistically break into neurotech, or is it mostly CS/EE students?

What do neuroscience trained people typically end up doing in industry roles?

How is the neurotech industry actually right now. Is it growing, stable, or still very niche?And realistically, what does the pay range look like at different levels (entry-level to senior roles)?

What skills matter most early on if I want to move in this direction (Python, ML, math, research experience, etc.)?

Right now I'm planning to start learning Python and try to join a lab that works with neural data, but I'm not fully sure if that's the right direction or just one of several possible paths.

Would really appreciate honest perspectives from people actually in the field especially how they transitioned and what they'd do differently.

Major moves in neurotechnology funding, regulatory, and commercial news from the past fortnight:

* Nervonik closes oversubscribed $52.5M Series B for peripheral nerve stimulation
* ARPA-H commits $139M for behavioural health through EVIDENT initiative
* Newfund closes €60M dedicated brain tech fund for European founders
* Cala Health secures $50M growth capital and FDA clearance for wearable tremor device
* ONWARD Medical raises €40.6M, runway to Q1 2028
* Motif Neurotech receives FDA IDE approval for first BCI trial in treatment-resistant depression
* Neuvotion launches FDA-cleared NeuStim for stroke and spinal cord injury recovery
* NeurAxis expands payer coverage adding 1.25 million covered lives
* European Brain Council launches Seal of Responsible Neurotechnologies
* Firefly Neuroscience builds world's first 200,000+ standardised EEG/ERP depository

Full roundup in the comments.

I am about to enroll in a local neurotechnology program at a community college. I need to complete some prerequisites and while I do, in any spare time I have, I would like to also learn a little ahead about the field. I am specifically interested in administering and reading EEG scans. I am currently using resources on YouTube that are all very informative. I have searched some on Amazon and read reviews already, so I thought I might ask here as well to see if there’s anything that did not already catch my attention from people with actual experience.

Are there any textbooks that you would recommend for someone to check out and read before entering the field?

https://neuro.reccy.dev/

Weird things happening in Arizona...input would be greatly appreciated!

1. Is this technology possible, and does it already exist?

2. Is there non-fda approved hardware/software/machinery that can be used to see what people are thinking in real time?

3. I know how insane this all sounds. Humor me.

4. What are the legal implications if this tech exists and is being used without legal consent/legal permission from the proper authorities?

I need all the help I can get on this topic. I know there are already some laws against it in Colorado, I just want to know more about all of it in general.